ALSO NOTED: Zila sells OTC brand; FDA accepts Santarus NDA; Callisto wins orphan drug status; and much more...

> Phoenix-based Zila has sold its OTC Zilactrin brand of oral and lip care products to Blairex Laboratories for $10.3 million. Article

> The FDA has accepted San Diego-based Santarus' NDA for Zegerid. Release

> Callisto Pharmacecuticals has received the FDA's orphan drug status for its experimental Annamycin, a therapy for acute myeloid leukemia. Release

> Takeda is selling its share of a joint animal drug program to its partner, Schering-Plough. Story

> Exagen Diagnostics, which is commercializing IVD kits based on genomic markers for prognostic or predictive testing, raised $7 million in Series B financing. Release

And Finally... The William and Melinda Gates Foundation has selected 47 projects to share $437 million in grant money to develop new public health solutions for the world's poorest people. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.